癌症患者对Covid-19疫苗接种的幽默免疫反应 - - ANRS0001S COV-POPART研究的结果
Liem Binh Luong Nguyen1, Lyvia Magloire2, Alexis François2
1INSERM, F-CRIN, Reseau Innovative Clinical Research in Vaccinology (IREIVAC), Paris, France; Centre d'Investigation Clinique Cochin Pasteur, Paris, France; Université de Paris, Paris, France.
癌症患者最初的COVID-19疫苗反应较弱,但在补充剂后获得了相似的免疫力. 这凸显了免疫力低下的个体,包括患有癌症的人, 接种补充剂的好处.
科学领域:
- 免疫学
- 癌症学
- 疫苗学
背景情况:
- 患有癌症的患者往往对疫苗的免疫反应减弱.
- 在初始COVID-19疫苗接种系列后,建议癌症患者服用强剂量.
- 了解癌症患者的疫苗免疫性对于公众健康至关重要.
研究的目的:
- 将癌症患者和健康成年人的COVID-19疫苗的幽默免疫性进行比较.
- 在初级疫苗接种和强制剂后评估免疫反应.
- 评估抗体水平和对抗SARS-CoV-2变种的中和能力.
主要方法:
- 前性队列研究 (ANRS0001S COV- POPART),包括没有先前感染SARS-CoV-2的75岁以上接种疫苗的参与者.
- 测量抗SARS-CoV-2IgG抗体的几何平均标位 (GMT) 和中和抗体一个月后的初级系列,一个和六个月后的增强剂.
- 在183名癌症患者和1173名健康对照人群中进行比较.
主要成果:
- 癌症患者在一次性治疗后IgG水平较低 (GMT132. 4与BAU/ mL332. 7).
- 癌症患者在服用强剂后,与对照人群相比,在一个月 (GMT 2146. 1 vs 1841. 3 BAU/ ml) 和六个月 (602. 0 vs 574. 4 BAU/ ml) 达到相似的IgG水平.
- 中和抗体水平证实了这些发现.
结论:
- 增强剂量显著提高了癌症患者的COVID-19疫苗免疫性.
- 癌症患者在补充剂后1个月和6个月表现出与对照组相比较的免疫反应.
- 这些发现支持对癌症患者进行再接种疫苗的建议和益处.
更多相关视频
07:33Preparation, Characteristics, Toxicity, and Efficacy Evaluation of the Nasal Self-Assembled Nanoemulsion Tumor Vaccine In Vitro and In Vivo
Published on: September 28, 2022
06:03Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays
Published on: September 20, 2024
相关概念视频
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Humoral Immune Responses
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Tumor Immunotherapy
Vaccinations
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
